Schopohl, J., Gu, F., Rubens, R., Van Gaal, L., Bertherat, J., Ligueros-Saylan, M., . . . Pivonello, R. (2014). Pasireotide can induce sustained decreases in urinary cortisol and provide clinical benefit in patients with Cushing’s disease: Results from an open-ended, open-label extension trial. Pituitary.
Styl ChicagoSchopohl, Jochen, et al. "Pasireotide Can Induce Sustained Decreases in Urinary Cortisol and Provide Clinical Benefit in Patients With Cushing’s Disease: Results From an Open-ended, Open-label Extension Trial." Pituitary 2014.
Citace podle MLASchopohl, Jochen, et al. "Pasireotide Can Induce Sustained Decreases in Urinary Cortisol and Provide Clinical Benefit in Patients With Cushing’s Disease: Results From an Open-ended, Open-label Extension Trial." Pituitary 2014.